Northern Trust
PRLD icon

Northern Trust’s Prelude Therapeutics PRLD Stock Holding History

Northern Trust’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
240,599
+190,479
+380% +$829K ﹤0.01% 3371
2026
Q1 		$171K Hold
50,120
– – ﹤0.01% 3986
2025
Q4 		$145K Buy
50,120
+13,699
+38% +$23.1K ﹤0.01% 4067
2025
Q3 		$52.4K Sell
36,421
-1,706
-4% -$1.71K ﹤0.01% 4280
2025
Q2 		$30.9K Sell
38,127
-78,780
-67% -$68.2K ﹤0.01% 4303
2025
Q1 		$89.8K Buy
116,907
+33,520
+40% +$31.3K ﹤0.01% 4141
2024
Q4 		$106K Sell
83,387
-22,990
-22% -$30.5K ﹤0.01% 4144
2024
Q3 		$220K Sell
106,377
-18,309
-15% -$84.8K ﹤0.01% 3855
2024
Q2 		$475K Buy
124,686
+2,539
+2% +$10.3K ﹤0.01% 3535
2024
Q1 		$579K Buy
122,147
+8,050
+7% +$31.3K ﹤0.01% 3516
2023
Q4 		$487K Sell
114,097
-1,421
-1% -$4.33K ﹤0.01% 3545
2023
Q3 		$357K Buy
115,518
+33,923
+42% +$127K ﹤0.01% 3611
2023
Q2 		$367K Buy
81,595
+60,428
+285% +$361K ﹤0.01% 3620
2023
Q1 		$121K Hold
21,167
– – ﹤0.01% 4035
2022
Q4 		$128K Hold
21,167
– – ﹤0.01% 4014
2022
Q3 		$140K Hold
21,167
– – ﹤0.01% 4010
2022
Q2 		$110K Sell
21,167
-80,739
-79% -$411K ﹤0.01% 4138
2022
Q1 		$703K Sell
101,906
-5,278
-5% -$48.3K ﹤0.01% 3597
2021
Q4 		$1.33M Buy
107,184
+759
+0.7% +$12.3K ﹤0.01% 3427
2021
Q3 		$3.33M Sell
106,425
-12,252
-10% -$397K ﹤0.01% 3001
2021
Q2 		$3.4M Buy
118,677
+3,178
+3% +$113K ﹤0.01% 3069
2021
Q1 		$5M Buy
115,499
+476
+0.4% +$31.6K ﹤0.01% 2737
2020
Q4 		$8.23M Buy
+115,023
New +$5.72M ﹤0.01% 2377

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Northern Trust's PRLD Position: Q2 2026 in Review

Northern Trust increased its Prelude Therapeutics (PRLD) stake by 380% in Q2 2026, buying an estimated $829K and bringing the position to 240,599 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3371.

Northern Trust first reported a position in PRLD in Q4 2020 and has held it in 23 quarters since. The position peaked at $8.23M in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Northern Trust held 240,599 shares of Prelude Therapeutics worth $1.28M as of Q2 2026.
  • Northern Trust bought 190,479 Prelude Therapeutics shares in Q2 2026, an estimated $829K.
  • Prelude Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3371 holding.
  • Northern Trust first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Northern Trust's Prelude Therapeutics position peaked at $8.23M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.